Genmab — Juli 2022

[E_L]

The bad news is the new name, Tecvayli, ffs who makes these up

[E_L]

Page or document not found | European Medicines Agency (EMA)

We are sorry, but the content you tried to access is unavailable at the link you used, which was either incorrect or out-of-date. To help you find what you are looking for, we have included some useful tips.

European Medicines Agency (EMA) (www.ema.europa.eu)

[Stroka]

Ingen reaktion på aktiekursen.

[Sukkeralf]

E L regarding the ODD withdrawned it could be due to the marked size being bigger than expected.

[deleted-user]

Thx E L you never disappoint likewise Genmab

[E_L]

Thx. OK, thx, I was thinking in the same direction Sukkeralf. I am even thinking, IF they would broaden the indication outside of myeloma at some point, and that way reach more patients in total, if they would then loose orphan for myeloma anyway

[E_L]

But anyway, who cares, product #6 on it's way

[Sukkeralf]

Yes indeed fantastic and admirable

[bibob]

Ikke helt med Genmab.

[JKY_VH]

Jep, Genmab fortsat i grønt

[Doublo]

God morgen Ja og udover den dejlige stigning på Genmab har der endelig været lidt positiv bevægelse i A.P. Møller som jeg desværre/heldigvis? har en hulens masse af!!

[bibob]

Historisk Vinge( gaard) sus.

[JKY_VH]

Ja, det var flot bibob;-)

[E_L]

the Japanese Epcoritamab trial starts recruiting again, with a few additional arms added https://www.clinicaltrials.gov/ct2/history/NCT04542824?A=5&B=6&C=merged#StudyPageTop

[bongobob]

Thanks EL. Apparently Genmab has 21 investigational sites in Japan. Is that with staff or just agreements with clinics

[E_L]

no, they are all hospitals; you can see that in the earlier version they mentioned the names of the hospitals. I don't know why they changed it to read like this , but have seen it in more trials with other companies also

[ProinvestorNEWS]

Akter/middag: Bavarian rykker på godkendelse - banker kommer lidt igen https://www.proinvestor.com/investornyt/854869/akter-middag-bavarian-rykker-pa-godkendelse-banker-kommer-lidt-igen

[Bulder]

Ofatumumab forbedrer RMS-patienters kognition https://mstidsskrift.dk/37-sygdom/767-ofatumumab-forbedrer-rms-patienters-kognition.html

[Helge_LarsenPI-redaktør]

"Medicinske tidsskrifter har tidligere beskrevet, hvorvidt studiet har konkluderet, at ofatumumab viser en bedre effekt på attakker og disability end teriflunomid".

[Helge_LarsenPI-redaktør]

Tak Bulder.